Lead Product(s): Pirfenidone
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Norwest Venture Partners
Deal Size: $35.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 27, 2020
Proceeds from the Series B expand the Avalyn's pipeline and will support the launch of a Phase II/III trial of AP01 in chronic lung allograft dysfunction (CLAD).